Literature DB >> 12427364

Intravenous pamidronate in treatment of non-steroidal anti-inflammatory drug-refractory ankylosing spondylitis.

Christopher T Ritchlin1.   

Abstract

Entities:  

Year:  2002        PMID： 12427364     DOI： 10.1007/s11926-002-0056-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  5 in total

1.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

2.  Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

Authors:  Filip Van Den Bosch; Elli Kruithof; Dominique Baeten; Annemie Herssens; Filip de Keyser; Herman Mielants; Eric M Veys
Journal:  Arthritis Rheum       Date:  2002-03

3.  Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?

Authors:  A Calin; J P Nakache; A Gueguen; H Zeidler; H Mielants; M Dougados
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580

Review 4.  Update on spondyloarthropathies.

Authors:  Muhammad Asim Khan
Journal:  Ann Intern Med       Date:  2002-06-18       Impact factor: 25.391

5.  Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis.

Authors:  S H Ralston; L Hacking; L Willocks; F Bruce; D A Pitkeathly
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.